Brief: TScan Therapeutics Q3 Net Income USD -29.887 Million
12/11/2024 12:00
Nov 12 (Reuters) - TScan Therapeutics Q3 basic EPS USD -0.25. * Q3 income from operations USD -32.622 million * Q3 operating expenses USD 33.671 million * Q3 collaboration and license revenue USD 1.049 million
Recent news on Tscan Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
U.S. STOCKS ON THE MOVE-FuelCell, Gold miners, NetApp
U.S. STOCKS ON THE MOVE-AEVEX, Sirius XM, PG&E
U.S. STOCKS ON THE MOVE-TScan Therapeutics, EOS Energy, Brown-Forman Corp
Brief: TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing